Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

Impact · against what's priced in

Kodiak's wider-than-expected loss and immediate equity dilution create short-term pressure, though its positive phase III data remains a primary value driver. For Regeneron, the confirmation of a competitive dosing interval for Zenkuda provides a concrete data point supporting the ongoing erosion of Eylea sales.

REGN−0.10

Already priced in

The price assumes

Eylea revenue erosion accelerates beyond what the current 17% decline already shows